Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BACKGROUND
Ivacaftor is generally safe and effective in patients aged 2 years and older who have cystic fibrosis and specific CFTR mutations. We assessed its use in children aged 12 to <24 months.
METHODS
The ARRIVAL study is a phase 3, single-arm, two-part, multicentre study. Eligible children were
Baz done ki pi konplè remèd fèy medsin te apiye nan syans
Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive
Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont. * Tout enfòmasyon baze sou rechèch syantifik pibliye